Sandu Pharmaceuticals Ltd

Sandu Pharmaceuticals Ltd

Sandu Pharmaceuticals Ltd has announced the Notice of Annual General Meeting and E-voting through a newspaper advertisement, as per Regulation 47 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Sandu Pharmaceuticals Ltd

Sandu Pharmaceuticals Ltd announced that the 41st Annual General Meeting (AGM) of the company will be held on September 11, 2026, through video conferencing. The company is sending a letter to shareholders who have not registered their email address with the Depository Participants (DP) or the Company/Registrar & Transfer Agent (RTA), providing the web-link to the Annual Report for FY 2026-27.

Sandu Pharmaceuticals Ltd

Sandu Pharmaceuticals Ltd has released its 41st Annual Report for the financial year 2025-26, highlighting a 23.187% increase in net profit despite market challenges, with a revenue of ₹6,993.45 lakhs. The company has strengthened its business foundations, enhanced operational efficiencies, and continued to invest in growth initiatives.

Sandu Pharmaceuticals Ltd

Sandu Pharmaceuticals Ltd has announced the 41st Annual General Meeting (AGM) to be held on September 11, 2026, through video conferencing or other audio-visual means. The meeting will consider and adopt the audited standalone financial statements for the financial year ended March 31, 2026, and reappoint the statutory auditors, M/s. Dave & Dave, for a term of five years. The company will also consider a dividend of 10% on paid-up capital.

Sandu Pharmaceuticals Ltd

Sandu Pharmaceuticals Ltd has announced the pre-despatch of its annual report and the 41st Annual General Meeting through electronic mode (Video Conference and other Audio visual means). The meeting will be held on September 11, 2026. The company has also announced a change of name for its promoter, MIHIR MOHAN KORGAONKAR, to MIHIR MOHAN.

Sandu Pharmaceuticals Ltd

Sandu Pharmaceuticals Ltd has published unaudited financial results for the quarter ended 30th June 2026 in the newspapers 'Navprabha' and 'Navhind Times'.

Sandu Pharmaceuticals Ltd

Sandu Pharmaceuticals Ltd has approved the unaudited standalone financial results for the quarter ended June 30, 2026, and recommended the proposal for obtaining approval of the members at the ensuing Annual General Meeting for the continuation of material related party transactions with M/s. Sandu Brothers Private Limited.

Sandu Pharmaceuticals Ltd

Sandu Pharmaceuticals Ltd has filed a statement of deviation and utilisation of funds for the quarter ended 30.06.2026, stating that the company has not deviated from the original objects for which the funds were raised through preferential issues in 2021 and 2022.

Sandu Pharmaceuticals Ltd

Sandu Pharmaceuticals Ltd has announced the appointment of M/s Dave & Dave Chartered Accountants as statutory auditors for a first term of five consecutive years, subject to approval of the shareholders.

Sandu Pharmaceuticals Ltd

Sandu Pharmaceuticals Ltd has announced the date of its annual General Meeting to be held on September 11, 2026. The meeting will be conducted through Video Conferencing (VC)/Other Audio-Visual Means (OAVM). The company has also recommended the proposal for obtaining approval of the Members at the ensuing Annual General Meeting for the continuation of Material Related Party Transactions with M/s. Sandu Brothers Private Limited.

Sandu Pharmaceuticals Ltd

Sandu Pharmaceuticals Ltd has announced the outcome of its Board Meeting held on August 11, 2026, where it approved the unaudited standalone financial results for the quarter ended June 30, 2026, and other business matters, including the record date for determining the eligibility of members entitled to receive the proposed dividend for the financial year ended March 31, 2026.

Sandu Pharmaceuticals Ltd

Sandu Pharmaceuticals Ltd has announced the outcome of its Board Meeting held on August 11, 2026, where it approved the unaudited standalone financial results for the quarter ended June 30, 2026, and other business matters. The company has also announced the book closure for its AGM on September 4-11, 2026, and recommended the approval of material related party transactions with Sandu Brothers Private Limited.

Sandu Pharmaceuticals Ltd

Sandu Pharmaceuticals Ltd announced its unaudited standalone financial results for the quarter ended June 30, 2026, which were approved by the Board of Directors. The company also approved the convening of its 41st Annual General Meeting to be held on September 11, 2026, through video conferencing. Additionally, the Board recommended the proposal for obtaining approval for material related party transactions with Sandu Brothers Private Limited and approved the appointment of Dave & Dave, Chartered Accountants as Statutory Auditors for a first term of five consecutive years.

Sandu Pharmaceuticals Ltd

Sandu Pharmaceuticals Ltd has announced unaudited financial results for the quarter ended June 30, 2026, with the board approving the results and recommending the appointment of new statutory auditors. The company also announced the convening of its 41st Annual General Meeting on September 11, 2026, and recommended the continuation of material related party transactions with Sandu Brothers Private Limited.

Sandu Pharmaceuticals Ltd

Sandu Pharmaceuticals Ltd announced its unaudited standalone financial results for the quarter ended June 30, 2026, which were approved by the Board of Directors. The company also approved the convening of its 41st Annual General Meeting on September 11, 2026, and recommended the continuation of material related party transactions with Sandu Brothers Private Limited. Additionally, the Board approved the appointment of M/s. Dave & Dave, Chartered Accountants, as the Statutory Auditors of the Company for a first term of five consecutive years.

Sandu Pharmaceuticals Ltd

Sandu Pharmaceuticals Ltd approved its unaudited standalone financial results for Q1 FY2026-27, with the board of directors taking note of the statement of utilisation and statement of deviation(s) in utilisation of funds for the quarter ended June 30, 2026. The company also approved the convening of its 41st Annual General Meeting on September 11, 2026, and recommended the proposal for obtaining approval of the members at the ensuing Annual General Meeting for the continuation of material related party transactions with M/s. Sandu Brothers Private Limited. Additionally, the board approved the appointment of M/s. Dave & Dave, Chartered Accountants, as statutory auditors of the company for a first term of five consecutive years.

Sandu Pharmaceuticals Ltd

Sandu Pharmaceuticals Ltd has scheduled a board meeting on 11th August 2026 to consider and approve the standalone unaudited financial results for the quarter ended 30th June 2026.